ATE410181T1 - Verwendung von intereferon gamma zur behandlung von herzhypertrophie - Google Patents

Verwendung von intereferon gamma zur behandlung von herzhypertrophie

Info

Publication number
ATE410181T1
ATE410181T1 AT06013719T AT06013719T ATE410181T1 AT E410181 T1 ATE410181 T1 AT E410181T1 AT 06013719 T AT06013719 T AT 06013719T AT 06013719 T AT06013719 T AT 06013719T AT E410181 T1 ATE410181 T1 AT E410181T1
Authority
AT
Austria
Prior art keywords
intereferon
gamma
cardiac hypertrophy
treat cardiac
treat
Prior art date
Application number
AT06013719T
Other languages
English (en)
Inventor
Hongkui Jin
Hsienwie Lu
Nicholas J Paoni
Renhui Yang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE410181T1 publication Critical patent/ATE410181T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT06013719T 1998-04-02 1999-03-19 Verwendung von intereferon gamma zur behandlung von herzhypertrophie ATE410181T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8044898P 1998-04-02 1998-04-02

Publications (1)

Publication Number Publication Date
ATE410181T1 true ATE410181T1 (de) 2008-10-15

Family

ID=22157456

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99912711T ATE332144T1 (de) 1998-04-02 1999-03-19 Behandlung von herzhypertrophie
AT06013719T ATE410181T1 (de) 1998-04-02 1999-03-19 Verwendung von intereferon gamma zur behandlung von herzhypertrophie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99912711T ATE332144T1 (de) 1998-04-02 1999-03-19 Behandlung von herzhypertrophie

Country Status (17)

Country Link
US (2) US6187304B1 (de)
EP (2) EP1067958B1 (de)
JP (2) JP5030329B2 (de)
CN (1) CN1201814C (de)
AR (1) AR018174A1 (de)
AT (2) ATE332144T1 (de)
AU (1) AU757910B2 (de)
BR (1) BR9909422A (de)
CA (1) CA2325442C (de)
DE (2) DE69932235T2 (de)
DK (2) DK1702623T3 (de)
ES (2) ES2267258T3 (de)
IL (1) IL138812A0 (de)
NZ (1) NZ506854A (de)
TW (1) TWI243682B (de)
WO (1) WO1999051260A2 (de)
ZA (1) ZA200004854B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192659A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP5030329B2 (ja) * 1998-04-02 2012-09-19 ジェネンテック， インコーポレイテッド 心臓肥大の処置
WO2001003720A2 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
US7838225B2 (en) * 1999-10-29 2010-11-23 Hologic, Inc. Methods for detection of a target nucleic acid by forming a cleavage structure using a reverse transcriptase
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
AU2002310922A1 (en) * 2001-05-04 2002-11-18 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
WO2003039455A2 (en) * 2001-11-06 2003-05-15 Applied Research Systems Ars Holding N.V. Methods of treating endometreosis
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
AU2003257588A1 (en) * 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
AU2003280812A1 (en) * 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
EP1522857A1 (de) * 2003-10-09 2005-04-13 Universiteit Maastricht Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
JP5866601B2 (ja) * 2008-06-18 2016-02-17 ザ テキサス エーアンドエム ユニバーシティ システムＴｈｅ Ｔｅｘａｓ Ａ＆Ｍ Ｕｎｉｖｅｒｓｉｔｙ Ｓｙｓｔｅｍ 医薬組成物の製造方法
USD647411S1 (en) 2011-01-12 2011-10-25 Rain Bird Corporation Water timer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582824A (en) 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4929544A (en) 1982-04-23 1990-05-29 Sri International Reagents, methods, and test kit for diagnosing/monitoring cancer in humans
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4944941A (en) 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
US5151265A (en) 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
SE462364B (sv) 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
ATE121945T1 (de) 1989-12-01 1995-05-15 Childrens Medical Center Verwendung von gamma-interferon zur herstellung eines medikaments für die behandlung von steroid- abhängigem asthma.
US6207641B1 (en) * 1995-03-10 2001-03-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
US5573762A (en) 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
US6214535B1 (en) * 1995-08-30 2001-04-10 Toray Industries, Inc. Method for testing cardiac myocarditis or cardiomyopathy
JP5030329B2 (ja) * 1998-04-02 2012-09-19 ジェネンテック， インコーポレイテッド 心臓肥大の処置

Also Published As

Publication number Publication date
AU757910B2 (en) 2003-03-13
JP2002510645A (ja) 2002-04-09
ZA200004854B (en) 2001-09-26
HK1099197A1 (en) 2007-08-10
WO1999051260A3 (en) 1999-12-09
EP1067958A2 (de) 2001-01-17
AU3102499A (en) 1999-10-25
EP1702623A3 (de) 2007-01-10
NZ506854A (en) 2003-07-25
BR9909422A (pt) 2001-09-11
DK1702623T3 (da) 2009-01-19
JP2009256375A (ja) 2009-11-05
ES2314786T3 (es) 2009-03-16
DK1067958T3 (da) 2006-11-06
HK1036019A1 (en) 2001-12-21
US6187304B1 (en) 2001-02-13
CN1300221A (zh) 2001-06-20
ATE332144T1 (de) 2006-07-15
DE69932235T2 (de) 2007-06-14
DE69939723D1 (de) 2008-11-20
IL138812A0 (en) 2001-10-31
JP5030329B2 (ja) 2012-09-19
EP1702623A2 (de) 2006-09-20
TWI243682B (en) 2005-11-21
CA2325442A1 (en) 1999-10-14
ES2267258T3 (es) 2007-03-01
AR018174A1 (es) 2001-10-31
EP1702623B1 (de) 2008-10-08
CA2325442C (en) 2011-10-11
EP1067958B1 (de) 2006-07-05
US6989364B1 (en) 2006-01-24
DE69932235D1 (de) 2006-08-17
CN1201814C (zh) 2005-05-18
WO1999051260A2 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
ATE300597T1 (de) Behandlung von geweben
DE69622154D1 (de) Verwendung von angiogenese-suppressoren zur hemmung des haarwuchses
ATE419856T1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE69831134D1 (de) Behandlung von wasser
ATE247987T1 (de) Behandlung zur beseitigung von gerüchen
ATE353218T1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
ATE410181T1 (de) Verwendung von intereferon gamma zur behandlung von herzhypertrophie
ATE281167T1 (de) Verwendung von makroliden zur behandlung von trockenen augen
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE339955T1 (de) Verwendung von escitalopram zur behandlung von generalisierten angstzuständen
DE69621447D1 (de) Verwendung von nitroflavonoide zur behandlung von angstzuständen
ATE326969T1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
ATE209891T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE60103503D1 (de) Verwendung von fsh zur behandlung von infertilität
ATE270545T1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE60012836D1 (de) Verwendung von Simethicone zur Behandlung der ulzerativen Kolitis
ATE255892T1 (de) Verwendung von antikonvulsiven derivaten zur behandlung von bulimia nervosa
ATE216885T1 (de) Verwendung von penciclovir zur behandlung von postherpetischer neuralgie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1702623

Country of ref document: EP